Big pharma is increasingly reluctant to undertake the development of new antibiotics, but Nabriva Therapeutics PLC's acquisition of San Diego, CA-based Zavante Therapeutics Inc. and its last-stage investigational agent, Contepo (fosfomycin, intravenous), indicates that smaller biopharma companies may be benefiting from the trend.
The Zavante acquisition, announced July 24, strengthens Nabriva's late-stage pipeline and the company's growing role as a leader in the development of novel antibiotics